Rhabdomyosarcoma Market: Global Industry Analysis and Forecast (2022-2027) by Type, Diagnosis, Treatment, and Region

Rhabdomyosarcoma Market size was valued at US$ 1.61 Bn. in 2021 and the total revenue is expected to grow at a CAGR of 3.7% through 2022 to 2027, reaching nearly US$ 2.0 Bn.

Rhabdomyosarcoma Market Overview:

Rhabdomyosarcoma Market is expected to reach at US$ 2.0 Bn. by 2027. A form of sarcoma is rhabdomyosarcoma. Sarcoma is a type of cancer that affects soft tissue (muscle), connective tissue (tendons and cartilage), and bone. Rhabdomyosarcoma is a cancer that starts in muscles that are related to bones and help the body move. However, it can start elsewhere in the body. Children with low-risk rhabdomyosarcoma have a 5-year survival rate of 70 percent to more than 90 percent. Children in the intermediate-risk group have a 5-year survival rate of roughly 50 percent to 70 percent. When cancer becomes high-risk and spreads widely throughout the body, the 5-year survival rate ranges from 20% to 30%. Rhabdomyosarcoma Market To know about the Research Methodology :- Request Free Sample Report

Rhabdomyosarcoma Market Dynamics:

The Rhabdomyosarcoma market is expected to rise due to a number of factors, including increased awareness of rhabdomyosarcoma and its rising occurrence. Furthermore, favourable government healthcare investments and increased demand for better treatments drive the market forward. During the forecast period, however, strict government regulations for product approval and high treatment costs are expected to hamper the Rhabdomyosarcoma market growth. In the United States, about 400 to 500 new cases of rhabdomyosarcoma (RMS) are diagnosed each year. Over the last few decades, the number of new cases has remained quite constant. Rhabdomyosarcomas are most commonly diagnosed in children and teenagers, with more than half of them occurring in children under the age of ten. RMS accounts for about 3% of all childhood malignancies. Embryonal Rhabdomyosarcomas (ERMS) are the most common type of tumour found in the head and neck, as well as the genital and urinary systems. ARMS (alveolar rhabdomyosarcoma) affects people of all ages and is more common in the arms, legs, and trunk (chest or abdomen). Boys are somewhat more likely than girls to have RMS. There does not appear to be any racial or ethnic group with an exceptionally high rate of RMS. The type of RMS, the location and size of the tumour, the results of surgery, and whether the cancer has metastasized all influence the prognosis (outlook) for persons with RMS (spread). Infants, older children, and adults have a better outlook than children aged 1 to 9. These are the various factors that are expected to drive the growth of the Rhabdomyosarcoma market during the forecast period.

Rhabdomyosarcoma Market Segment Analysis:

Based on the Type, the market is segmented into Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma, and Others. Embryonal Rhabdomyosarcoma type segment is expected to grow rapidly at a CAGR of xx% during the forecast period 2022-2027. Embryonal rhabdomyosarcoma is a malignant neoplasm that mimics embryonic striated muscle. It has botryoid, spindle cell, and anaplastic subtypes, as well as deletions on the short arm of chromosome 11. The head and neck region, the genitals, or the urinary tract are the most common sites for this tumour to appear. Children under the age of six are most commonly affected. Despite the fact that embryonal RMS is a fast-growing tumour, most instances respond effectively to vigorous treatment. Based on the Treatment, the market is segmented into Surgery, Radiation Therapy, Chemotherapy, and Stem Cell Therapy. Chemotherapy treatment segment is expected to hold the largest market share of xx% by 2027. This is due to its efficacious treatment for reducing the risk of cancer recurrence and high patient preference Chemotherapy involves injecting drugs into the bloodstream. The medications either destroy or prevent cancer cells from proliferating and spreading. Chemotherapy is given to most children with rhabdomyosarcoma to reduce the chances of the tumour returning. Rhabdomyosarcoma Market

Rhabdomyosarcoma Market Regional Insights:

North America region is expected to dominate the Rhabdomyosarcoma Market during the forecast period 2022-2027. North America region is expected to hold the largest market share of xx% by 2027. This is due to the high frequency of RMS and the well-established healthcare infrastructure in the North America region. Many strategic methods are being employed by companies in the North America rhabdomyosarcoma market to improve their product and service offerings. For example, in 2016, Pfizer invested US$ 6.00 million in Bioinvent for a Myeloid Cell Antibody collaboration. Bioinvent is developing a number of cancer medications, including TB-403, a monoclonal antibody that targets placental growth factor as a potential treatment for alveolar RMS, medulloblastoma, and other conditions. This medication is currently in Phase 2 testing. Europe region is expected to grow rapidly at a CAGR of xx% during the forecast period 2022-2027. This is due to the well-developed healthcare infrastructure in the Europe region. Rhabdomyosarcoma Market The objective of the report is to present a comprehensive analysis of the Global Rhabdomyosarcoma Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Global Rhabdomyosarcoma Market dynamic, structure by analyzing the market segments and project the Global Rhabdomyosarcoma Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Rhabdomyosarcoma Market make the report investor’s guide.

Rhabdomyosarcoma Market Scope: Inquiry Before Buying

Global Rhabdomyosarcoma Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US $ 1.61 Bn.
Forecast Period 2022 to 2027 CAGR: 3.7% Market Size in 2027: US $ 2.0 Bn.
Segments Covered: by Type • Embryonal Rhabdomyosarcoma • Alveolar Rhabdomyosarcoma • Others
by Diagnosis • Imaging Tests • X-Ray • CT Scan • MRI Scan • PET Scan • Bone Scan • Biopsy • Needle Biopsy • Surgical Biopsy
by Treatment • Surgery • Radiation Therapy • Chemotherapy • Stem Cell Therapy

Rhabdomyosarcoma Market, by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Rhabdomyosarcoma Market Key Players

Boehringer Ingelheim International GmbH • Pfizer Inc. • Eli Lilly & Company • Novartis AG • Bristol Myers Squibb Company • TAIHO ONCOLOGY, INC • Oasmia Pharmaceutical • Bellicum Pharmaceuticals, Inc. • CELGENE CORPORATION • Eisai Co., Ltd. • MacroGenics, Inc. • NantKwest • Tarveda Therapeutics. • Exelixis, Inc. • Ipsen Pharma • Ovation Pharmaceuticals Frequently Asked Questions: 1] Which region is expected to hold the highest share in the Rhabdomyosarcoma Market? Ans. North America is expected to hold the highest share in the Rhabdomyosarcoma Market. 2] Who are the top key players in the Rhabdomyosarcoma Market? Ans. Boehringer Ingelheim International GmbH, Pfizer Inc., Eli Lilly & Company, Novartis AG, and Bristol Myers Squibb Company are the top key players in the Rhabdomyosarcoma Market. 3] Which segment holds the largest market share in the Rhabdomyosarcoma market by 2027? Ans. Chemotherapy treatment segment hold the largest market share in the Rhabdomyosarcoma Market by 2027. 4] What is the market size of the Rhabdomyosarcoma market by 2027? Ans. The market size of the Rhabdomyosarcoma Market is expected to reach US $2.0 Bn. by 2027. 5] What was the market size of the Rhabdomyosarcoma market in 2021? Ans. The market size of the Rhabdomyosarcoma Market was worth US $1.61 Bn. in 2021.
1. Global Rhabdomyosarcoma Market: Research Methodology 2. Global Rhabdomyosarcoma Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Rhabdomyosarcoma Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Rhabdomyosarcoma Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Rhabdomyosarcoma Market Segmentation 4.1 Global Rhabdomyosarcoma Market, by Type (2022-2027) • Embryonal Rhabdomyosarcoma • Alveolar Rhabdomyosarcoma • Others 4.2 Global Rhabdomyosarcoma Market, by Diagnosis (2022-2027) • Imaging Tests • X-Ray • CT Scan • MRI Scan • PET Scan • Bone Scan • Biopsy • Needle Biopsy • Surgical Biopsy 4.3 Global Rhabdomyosarcoma Market, by Treatment (2022-2027) • Surgery • Radiation Therapy • Chemotherapy • Stem Cell Therapy 5. North America Rhabdomyosarcoma Market (2022-2027) 5.1 North America Rhabdomyosarcoma Market, by Type (2022-2027) • Embryonal Rhabdomyosarcoma • Alveolar Rhabdomyosarcoma • Others 5.2 North America Rhabdomyosarcoma Market, by Diagnosis (2022-2027) • Imaging Tests • X-Ray • CT Scan • MRI Scan • PET Scan • Bone Scan • Biopsy • Needle Biopsy • Surgical Biopsy 5.3 North America Rhabdomyosarcoma Market, by Treatment (2022-2027) • Surgery • Radiation Therapy • Chemotherapy • Stem Cell Therapy 5.4 North America Rhabdomyosarcoma Market, by Country (2022-2027) • United States • Canada • Mexico 6. Europe Rhabdomyosarcoma Market (2022-2027) 6.1. Europe Rhabdomyosarcoma Market, by Type (2022-2027) 6.2. Europe Rhabdomyosarcoma Market, by Diagnosis (2022-2027) 6.3. Europe Rhabdomyosarcoma Market, by Treatment (2022-2027) 6.4. Europe Rhabdomyosarcoma Market, by Country (2022-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Rhabdomyosarcoma Market (2022-2027) 7.1. Asia Pacific Rhabdomyosarcoma Market, by Type (2022-2027) 7.2. Asia Pacific Rhabdomyosarcoma Market, by Diagnosis (2022-2027) 7.3. Asia Pacific Rhabdomyosarcoma Market, by Treatment (2022-2027) 7.4. Asia Pacific Rhabdomyosarcoma Market, by Country (2022-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. South America Rhabdomyosarcoma Market (2022-2027) 8.1. South America Rhabdomyosarcoma Market, by Type (2022-2027) 8.2. South America Rhabdomyosarcoma Market, by Diagnosis (2022-2027) 8.3. South America Rhabdomyosarcoma Market, by Treatment (2022-2027) 8.4. South America Rhabdomyosarcoma Market, by Country (2022-2027) • Brazil • Argentina • Rest Of South America 9. Middle East and Africa Rhabdomyosarcoma Market (2022-2027) 9.1 Middle East and Africa Rhabdomyosarcoma Market, by Type (2022-2027) 9.2. Middle East and Africa Rhabdomyosarcoma Market, by Diagnosis (2022-2027) 9.3. Middle East and Africa Rhabdomyosarcoma Market, by Treatment (2022-2027) 9.4. Middle East and Africa Rhabdomyosarcoma Market, by Country (2022-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 10. Company Profile: Key players 10.1. Boehringer Ingelheim International GmbH 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Pfizer Inc. 10.3. Eli Lilly & Company 10.4. Novartis AG 10.5. Bristol Myers Squibb Company 10.6. TAIHO ONCOLOGY, INC 10.7. Oasmia Pharmaceutical 10.8. Bellicum Pharmaceuticals, Inc. 10.9. CELGENE CORPORATION 10.10. Eisai Co., Ltd. 10.11. MacroGenics, Inc. 10.12. NantKwest 10.13. Tarveda Therapeutics. 10.14. Exelixis, Inc. 10.15. Ipsen Pharma 10.16. Ovation Pharmaceuticals

About This Report

Report ID 66002
Category Healthcare
Published Date July 2020
Updated Date Mar 2022
Contact Us